RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

Share :
Published: 12 Sep 2022
Views: 448
Prof Chris Parker - Institute of Cancer Research, Sutton, UK

Prof Chris Parker presents the RADICALS-HD trial which will ensure clinicians can better tailor treatment for prostate cancer patients following surgery and help facilitate important discussions. 

The trial showed encouraging results for radiotherapy without hormone therapy so some patients, concerned with upsetting side effects of hormone therapy, can be reassured this treatment alone is a good option. 

For other patients, at higher risk of their cancer returning, two years of hormone therapy is more effective than six months of treatment.